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Aim: Classic activating mutations L858R and deletions in exon 19 (19del) in the gene for epidermal growth factor receptor (EGFR) 
are associated with sensitivity of the non-small cell lung cancer (NSCLC) to therapy with tyrosine kinase inhibitors (TKI). In-
sertions in EGFR exon 19 (19ins) are rare mutations in NSCLC; response of cases with 19ins to TKI is not well studied. Here 
we report a case of NSCLC with 19ins in a Russian patient who was treated with gefitinib. We also overview cases of 19ins re-
ported in the literature. Case description: A 48 years old female Russian patient was diagnosed with adenocarcinoma of the lung 
(T3N2M1, stage IV). Mutation 19ins was detected in the tumor biopsy by fragment analysis and genotyped by Sanger sequenc-
ing as p.I744_K745insKIPVAI. Treatment with gefitinib (250 mg/day) resulted in clinical and radiological improvements scored 
as partial response that lasted 12 months. Conclusion: Treatment with gefitinib of lung adenocarcinoma that carries mutation EGFR 
19ins can result in durable response.
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Some cases of non-small cell lung cancer (NSCLC) 
carry activating mutations in the epidermal growth 
factor receptor (EGFR) gene which are associated 
with sensitivity of the tumor to tyrosine kinase in-
hibitors (TKI). Frequency of the mutations varies from 
2 to 40% in different groups of patients and positively 
correlates with adenocarcinoma histology, female 
gender, non-smoker status and Asian ethnicity [1]. 
Most of activating mutations in EGFR gene (85–90%) 
are small in-frame deletions in exon 19 (19del), 
or missense mutation L858R. Insertions in EGFR exon 
19 (19ins) are rare mutations which comprise about 
1% among cases of NSCLC with mutant EGFR [2]. 
Due to the small number of patients response to TKI 
of cases with 19ins is not well studied. Here we de-
scribe a case of NSCLC with 19ins in a Russian patient 
that was treated with gefitinib.
CASE REPORT
Female Caucasian patient, 48 years old, non-
smoker, was diagnosed with lung cancer (T3N2M1, 
stage IV). Major clinical symptoms were pronounced 
dyspnea and cough with large amount of sputum 
(up to 500 ml/day). Computed tomography (CT) scans 
showed peripheral tumor of the right lung (Fig. 1, a). 
Thoracoscopic biopsy of the right lung was performed 
to verify morphological diagnosis. Biopsy of the tumor 
had histology of adenocarcinoma.
Molecular tests of the DNA from FFPE tumor biopsy 
did not find common mutations EGFR L858R or 19del. 
The assays we used are based on allele-specific real-
time polymerase chain reaction (PCR) for mutation 
L858R and wild-type blocking real-time PCR for 19del 
(BioLink, Russia). Some rare deletions as well as inser-
tions in exon 19 are not included in the real-time PCR 
assay, therefore we test for these mutations by frag-
ment analysis of the DNA after PCR with forward primer 
5'-dGGTGAGAAAGTTAAAATTCCCGTCGC and reverse 
primer 5'-dTCGAGGATTTCCTTGTTGGCTTTC. Frag-
ment analysis of the DNA detected insertion in EGFR 
exon 19 (Fig. 2, a, case # 692). Sanger sequencing 
of the DNA showed duplication of 18bp sequence 
AAAATTCCCGTCGCTATC (c.2215_2232dup) that re-
sulted in mutation p.I744_K745insKIPVAI (Fig. 2, b).
During the first month after diagnosis the patient 
had 1 course of chemotherapy (carboplatin AUC5, eto-
poside 120 mg/m2). After detection of the EGFR muta-
tion patient was switched to gefitinib (250 mg/day). 
One month after treatment with gefitinib there was 
pronounced improvement in clinical symptoms (mini-
mal dyspnea at physical exercise, rare cough with 
small amount of sputum). Due to diffused infiltration 
of the lung parenchyma and pleuritis it was not pos-
sible to select target on CT scans for evaluation of re-
sponse according to RECIST 1.1. Case was scored 
as partial response based on clinical improvements 
in patient performance from ECOG 2 to ECOG0-1 and 
radiological improvements (dimi nished ground-glass 
opacities and decreased amount of fluid in pleural 
cavity on CT scans) after 2 months of treatment with 
gefitinib (Fig. 1, b). CT scans were performed every 
2 months. Radiological and clinical disease progres-
sion was revealed after 12 months of gefitinib treat-
ment. After that patient was switched to paclitaxel 
(175 mg/m2) and due to lack of clinical response after 
3 courses of paclitaxel the best available supportive 
care was provided. Patient died 18 months after initia-
tion of treatment.
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Fig. 1. CT scans of chest before (a) and after 2 months of treat-
ment with gefitinib (b). Note large amount of fluid in pleural cavity 
before treatment (arrow)
Fig. 2. Molecular analysis of a lung cancer case with insertion 
in EGFR exon 19. (a) Fragment analysis of EGFR exon 19. Picture 
of gel-electrophoresis of PCR DNA is shown with bands corre-
sponding to exon 19 wild-type (WT), deletion (arrow) and inser-
tion (arrow head). Lane 1 — 100bp DNA marker (M); lanes 2–5 — 
DNA from FFPE tumor samples; lane 6 — blank (B); lane 7 — DNA 
standard with 15bp deletion in exon 19 (p.E746_A750delELREA). 
(b) Sanger sequencing of EGFR exon 19 in the tumor DNA # 692. 
Duplicated 18bp sequence in the tumor DNA is underlined, 
the insertion that resulted in mutation p.I744_K745insKIPVAI 
is shown in a box
DISCUSSION
In our laboratory the single 19ins case was detected 
among 421 patients with NSCLC that included also 
37 cases of 19del and 33 cases of L858R (Table). In an-
other study of Russian patients with lung cancer 19ins 
was detected in 4 cases in addition to 455 cases with 
mutations 19del and L858R [3]. Frequency of 19ins 
among EGFR mutant cases in Russia based on Iyevleva 
et al. [3] and our study together was 5/530 (0.9%). 
This frequency is similar to 8/601 (1.3%) of cases with 
mutant EGFR in study in United States [2]. Interest-
ingly, 19ins comprised only 7/2581 (0.3%) of the lung 
cancer cases in Asian patients with mutant EGFR [4, 
5]. Much lower frequency of 19ins among Asian pa-
tients with mutant EGFR may be due to differences 
between ethnic groups or between methods to detect 
mutations in EGFR.
Table. Frequency of mutations EGFR L858R, 19del and 19ins in NSCLC 
in different studies
Patients, 
N (%)
EGFR+, N 
(%)1
19del, N 
(%)2
L858R, N 
(%)2
19ins, 
N (%)2
Coun-
try Reference
421
(100.0) 71 (16.9) 37 (52.1) 33 (46.5) 1 (1.4) Russia This study
2276
(100.0) 459 (20.2) 288 (62.7) 167 (36.4) 4 (0.9) Russia [3]
3026
(100.0) 601 (19.9) 347 (57.7) 246 (40.9) 8 (1.3) USA [2]
2018
(100.0) 860 (42.6) na na 3 (0.3)
Hong 
Kong [4]
3534
(100.0) 1721 (48.7) na na 4 (0.2) Taiwan [5]
Note: 1mutant EGFR cases as percent of all patients; 2percent of cases with 
the mutation in comparison to all cases with mutant EGFR; na — not available.
Published data of response of lung cancers with 
19ins to TKI (gefitinib, erlotinib or afatinib) includes 
22 cases that were reviewed recently [5]. By searching 
PubMed in addition to the cases reviewed by Lin et al. 
[5] we found a report of Arabic female lung cancer 
patient with 19ins responding to erlotinib [6]. Together 
with our study total number of patients with 19ins 
treated with TKI is limited to 24 cases would-wide. 
Patients were predominantly female non-smokers 
and most cases were sensitive to TKI. We observed 
a case of lung adenocarcinoma (stage IV) with muta-
tion p.I744_K745insKIPVAI that had partial response 
to gefitinib that lasted 12 months. Combined with data 
from Iyevleva et al. [3] time to progression of Russian 
patients (n = 4) with 19ins on gefitinib was on ave rage 
9.3 months (range 5–12 months). For comparison, 
Caucasion patients who had lung cancer with mutant 
EGFR and were treated with gefitinib in the first-line 
had progression free survival 9.7 months [7]. It ap-
pears that sensitivity of tumors with 19ins and dura-
tion of response to TKI is similar to classic mutations 
in EGFR gene, however data on larger number of pa-
tients is needed.
In conclusion, our report contributes to small 
number of cases in other studies indicating sensitivity 
of the lung adenocarcinoma with insertions in exon 
19 to thera py with TKI. The study also shows clinical 
usefulness of fragment analysis of EGFR exon 19 in ad-
dition to real-time PCR assays that do not include 
mutation 19ins.
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